Eli Lilly has begun the week with a bang. Early Monday morning, AdvanCell and OliX Pharmaceuticals put out news that the Big ...

Operator Ladies and gentlemen, thank you for standing by and welcome to the Lilly Q4 2024 earnings call. [Operator ...

A two-level pickleball and entertainment venue at the Natick Mall is now complete with the opening of all of its four ...

Kochi: Expediting the procedures regarding the second phase of development works of Seaport-Airport Road, a memorandum of understanding (MoU) was exchanged between the National Armed Depot (NAD ...

Every year, a new list of players is inducted, and this time, there are 15 finalists left, including former New York Giants quarterback Eli Manning, who is attempting to make it in his first year ...

The 19-year-old phenom, who is set to finally take over as a starter in the 2025 season, said he has been bullied by his famous uncles, Peyton and Eli, and they have even given him wedgies.

The firm completed the 346K SF Lilly Seaport Innovation Center in Fort Point in partnership with Alexandria Real Estate Equities last year, and Eli Lilly ... I've been in Boston," Griffin said.

With its offering of tirzepatide (branded as Mounjaro and Zepbound), Eli Lilly and Co. (NYSE: LLY) was another key pharma player in this new type of treatment for diabetes and obesity.

Eli Lilly's small pop was due to the latest developments in the lab reported by Novo Nordisk (NYSE: NVO), which, like the U.S. company, is doing brisk business with a weight loss drug: Wegovy ...

Commuters bound for Boston’s Seaport will soon have a new way to complete their trips when the Massachusetts Convention Center Authority launches a new ferry route to the Raymond L. Flynn Marine ...

As evidence has mounted that new diabetes and weight loss drugs can provide a variety of health benefits, the FDA has approved Novo Nordisk’s semaglutide for heart disease and Eli Lilly’s ...

Eli Lilly's Q4 FY24 guidance adjustment is due to supply chain factors, not demand, creating an attractive buying opportunity with a 'Buy' rating. Despite a modest 0.6% revenue reduction ...